Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is .
Teens headed to prison for role in fatal ambush after school fight mlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mlive.com Daily Mail and Mail on Sunday newspapers.
AbbottNew efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trialsAbbott's Diversity in Clinical Trials
The pandemic has changed nursing, raising questions about the future of nursing and most immediately, who wants to even be a nurse. This crisis in nursing is causing nursing educators to quickly rethink how they train their students and making health systems rethink how they recruit and retain nurses.